首页> 美国卫生研究院文献>British Journal of Cancer >An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients
【2h】

An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients

机译:内部和外部验证的列线图可预测伊立替康诱发晚期大肠癌患者发生严重中性粒细胞减少的风险

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: In Asians, the risk of irinotecan-induced severe toxicities is related in part to UGT1A1*6 (UGT, UDP glucuronosyltransferase) and UGT1A1*28, variant alleles that reduce the elimination of SN-38, the active metabolite of irinotecan. We prospectively studied the relation between the UGT1A1 genotype and the safety of irinotecan-based regimens in Japanese patients with advanced colorectal cancer, and then constructed a nomogram for predicting the risk of severe neutropenia in the first treatment cycle.
机译:背景:在亚洲人中,伊立替康引起严重毒性的风险部分与UGT1A1 * 6(UGT,UDP葡萄糖醛糖基转移酶)和UGT1A1 * 28有关,这些等位基因降低了伊立替康的活性代谢产物SN-38的消除。我们对日本晚期结直肠癌患者的UGT1A1基因型与基于伊立替康的方案安全性之间的关系进行了前瞻性研究,然后构建了诺模图以预测第一个治疗周期中严重中性粒细胞减少的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号